Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Clinical Cancer Research (online first doi: 10.1158/1078-0432.CCR-21-0560).
STOCKHOLM, Aug. 12, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Clinical Cancer Research (online first doi: 10.1158/1078-0432.CCR-21-0560). This clinical study was conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Results of the open-label clinical trial of the topical HDAC inhibitor, remetinostat, as neoadjuvant treatment for BCC were reported. Thirty-three per-protocol tumors from 25 participants were included in the analysis. The overall response rate (ORR), defined as the proportion of tumors achieving more than 30% decrease in the longest diameter from baseline to week 8, was 69.7% [90% confidence interval (CI), 54%–82.5%]. On pathologic examination, 54.8% of tumors demonstrated complete resolution. No systemic adverse events were reported. The results were also commented on in a press release by the American Association for Cancer Research (AACR): https://www.aacr.org/patients-caregivers/progress-against-cancer/a-new-type-of-gel-shows-promise-against-common-type-of-skin-cancer/ "These very positive results further support the potential of remetinostat to be used in additional skin-associated cancers beyond cutaneous T-cell lymphoma (CTCL)", said Magnus Christensen, interim CEO of Medivir. About remetinostat About Medivir This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Medivir |
||||
Company Codes: Stockholm:MVIRB, Bloomberg:MVIRB@SS, ISIN:SE0000273294, RICS:MVIRB.ST |